8-K: CareDx Reports Q2 Growth, Narrows 2025 Revenue Outlook

CareDx, Inc. announced its second quarter 2025 financial results, reporting significant adjusted revenue growth and appointing a new Chief Financial Officer.

Summary

• Reported Q2 2025 revenue of $86.7 million, with adjusted revenue reaching $90.5 million, a 14% increase year-over-year.
• Testing services volume grew 13% year-over-year to approximately 49,500, with AlloSure Kidney testing volumes increasing nearly 20%.
• GAAP net loss for Q2 2025 was $8.6 million, compared to a $4.6 million loss in Q2 2024.
• Non-GAAP net income was $5.6 million, down from $13.6 million in Q2 2024.
• Adjusted EBITDA gain was $9.1 million, a significant improvement from a $0.3 million loss in Q2 2024.
• Cash, cash equivalents, and marketable securities stood at $186 million as of June 30, 2025, after a $50 million share repurchase, with no debt.
• Full-year 2025 revenue guidance was narrowed to $367 million to $373 million, while adjusted EBITDA guidance remained at $29 million to $33 million.
• Nathan Smith was appointed as the new Chief Financial Officer, effective August 7, 2025, succeeding Abhishek Jain who retired.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While GAAP net loss widened and non-GAAP net income decreased, the company demonstrated strong underlying business growth with significant increases in adjusted revenue and testing volumes. The substantial improvement in adjusted EBITDA, strong cash position, and maintained full-year adjusted EBITDA guidance are key positives. The CFO transition appears well-managed, and new product launches indicate continued innovation. The negative impact on reported revenue from prior period adjustments is a technical accounting issue rather than a core operational decline.

Positives

• Adjusted revenue increased by 14% year-over-year to $90.5 million, indicating strong underlying business performance.
• Testing services volume grew for the eighth consecutive quarter, up 13% year-over-year to 49,500.
• AlloSure Kidney testing volumes showed robust growth, increasing nearly 20% year-over-year.
• Adjusted EBITDA improved significantly to a gain of $9.1 million, compared to a loss of $0.3 million in the prior year period.
• The company maintains a strong cash position of $186 million with no debt, even after a $50 million share repurchase.
• Patient and Digital Solutions revenue increased by 19% to $12.8 million, and Product revenue increased by 12% to $11.8 million.
• The draft LCD affirms surveillance testing coverage for solid organ transplant rejection, which is favorable for the company's services.
• Launched AlloSure Plus, an AI-driven diagnostic platform, enhancing product offerings.
• Successfully installed EPIC environment and initiated multiple customer pilots in Q3, indicating progress in digital solutions integration.

Negatives

• Reported GAAP revenue decreased by 6% year-over-year to $86.7 million, primarily due to a $3.8 million write-off of aged receivables.
• GAAP testing services revenue decreased by 13% year-over-year to $62.0 million.
• GAAP net loss widened to $8.6 million in Q2 2025 from $4.6 million in Q2 2024.
• Non-GAAP net income decreased to $5.6 million from $13.6 million in the second quarter of 2024.

Risks

• Forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and beyond the company's control, including general economic and market factors, and global economic and marketplace uncertainties.
• The company's financial results could differ materially and adversely from projections due to factors discussed in its SEC filings, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2024.

Future Outlook

The company narrowed its full-year 2025 revenue guidance to a range of $367 million to $373 million, reflecting increased certainty. It maintained its full-year 2025 adjusted EBITDA guidance in the range of $29 million to $33 million, indicating continued confidence in profitability. The company also expects to comment on the draft LCD for surveillance testing coverage by August 31, 2025, and has initiated multiple customer pilots for its EPIC environment in the third quarter.

Management Comments

• "CareDx had a strong second quarter. Volume growth accelerated, led by AlloSure kidney testing which was up nearly 20% year-over-year."
• "Our cash collections also improved considerably, and coupled with financial discipline, contributed to a substantial adjusted EBITDA improvement."
• "We had an exceptional showing at the World Transplant Congress where data supporting the use of AlloSure Kidney was highlighted in large, prospective, multi-center studies as being the most significant biomarker for detecting organ rejection."
• "Our evidence and differentiated products, including the launch of AlloSure Plus, are setting us apart as the leader in transplant care."

Industry Context

CareDx operates in the precision medicine and transplant care industry, a specialized and high-value segment of healthcare. The continued growth in testing services volumes, particularly for AlloSure Kidney, and the affirmation of surveillance testing coverage by the draft LCD, suggest a favorable regulatory and market environment for transplant diagnostics. The launch of AlloSure Plus, an AI-driven diagnostic platform, aligns with broader industry trends towards integrating advanced analytics and artificial intelligence into healthcare solutions to improve diagnostic accuracy and patient outcomes. The company's strong presence at the World Transplant Congress underscores its leadership and commitment to advancing transplant science.

Management Changes

Corporate Governance

Legal Proceedings

• The company reported an 'Accrued litigation settlement expense' of $20.25 million as of June 30, 2025, and a 'Litigation settlement expense' of $350 thousand for the three months ended June 30, 2025, indicating ongoing or recently settled legal matters.

Related Party Transactions

• There are no reportable family relationships or related party transactions (as defined in Item 404(a) of Regulation S-K) involving the Company and the newly appointed CFO, Nathan Smith.

Stakeholder Impact

• **Shareholders**: The $50 million share repurchase indicates a return of capital to shareholders. The narrowed revenue guidance and maintained adjusted EBITDA guidance provide clearer financial outlook. The CFO change aims to strengthen financial leadership.
• **Employees**: The appointment of a new CFO and the structured departure of the previous CFO indicate management stability and continuity. The new CFO's compensation package includes performance-based incentives.
• **Customers**: The launch of AlloSure Plus and the successful installation of EPIC environment with customer pilots suggest enhanced product offerings and improved service integration, potentially benefiting transplant centers and patients.
• **Creditors**: The company reports no debt as of June 30, 2025, indicating a strong balance sheet and low credit risk.

Next Steps

• CareDx intends to comment on aspects of the draft LCD for surveillance testing coverage during the open comment period, which ends August 31, 2025.
• Multiple customer pilots for the EPIC environment were initiated in the third quarter.
• The Offer Letter, Change of Control and Severance Agreement, and CIIA Agreement for Nathan Smith will be filed as exhibits to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2025.
• The Release Agreement and Consulting Agreement with Abhishek Jain will be filed as exhibits to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025.

Key Dates

Recommendation

While CareDx demonstrated strong underlying business growth with significant increases in adjusted revenue and testing volumes, and a substantial improvement in adjusted EBITDA, the widening GAAP net loss and decrease in non-GAAP net income present a mixed financial picture. The company's strong cash position and lack of debt are positives, and the CFO transition appears well-managed. However, the discrepancy between GAAP and adjusted results, particularly the negative impact of prior period revenue adjustments on reported revenue, warrants a cautious approach. The stock is likely to remain sensitive to future GAAP profitability trends and the resolution of prior period revenue issues. Therefore, a 'hold' recommendation is appropriate, advising investors to monitor the company's ability to translate adjusted growth into sustainable GAAP profitability.

Keywords

CareDx, CDNA, Transplant, Precision Medicine, AlloSure, Kidney Testing, Organ Rejection, Biomarker, Financial Results, Q2 2025, CFO Appointment, SEC Filing, Healthcare Solutions, Genomics, EBITDA, Revenue Guidance